Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

• § Age > or equal to 18 years.§
• Performance status inferior or equal to 1 (WHO criteria)
• Histologically proven breast cancer, non metastatic, with clinical tumor diameter > or equal to 2 cm.
• HR negative and HER 2 negative.
• Clinical stage II and IIIa.
• Non prior treated patients either by surgery, radiotherapy, hormonotherapy or chemotherapy.§
• Adequate hematological, renal and hepatic functions : neutrophils > 2.109 /L, platelets > 100.109 /L, Hb > 10 g/dL, normal bilirubin, ASAT and ALAT inferior or equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine \< 140 µmol/L or creatinine clearance > 60 mL/min.§
• Written informed consent§
• Affiliation with social security system (or profit being of such a mode) according to terms' of the law of August 9, 2004.

Exclusion Criteria:

• Male patient.
• Pregnant or lactating women or childbearing potential with no efficacy contraception.
• Other breast cancer form and particularly inflammatory form and/or negliged (T4b or T4d).§
• Non measurable tumor.
• Prior surgery or primary axillary dissection.
• Prior treatment for this new breast cancer.
• Under guardianship patient
• Patient with antecedent of second cancer, excepted in situ uterine carcinoma or baso-cellular cutaneous cancer considered as definitively cured.
• Patient with an associated pathology considered incompatible with the study.§ Cardiac, renal, medullar, respiratory or hepatic insufficiency.
• Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles in CNS or metastasis.
• Peripheral neuropathy > grade 2 NCI-CTC (version 3.0)
• Previous allergy with polysorbate 80.
• Concomitant treatment with a drug tested in a clinical trial, participation to another clinical study, for the last thirty days or prior chemotherapy.
• Patients non stable for the following 6 months or leaving at a great distance of the participating center.